Clinical Trial Update: Immunogenicity AND Safety Study of the 11 Valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) [Phase 2]

View source ↗

Summary

Phase 2 immunogenicity and safety study of an 11-valent HPV vaccine completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hpv Infection
• Hpv-related Cervical Carcinoma

Drugs mentioned

• Hansenulapolymorpha

Snippet

Sponsor: National Vaccine and Serum Institute, China | Conditions: HPV Infection, HPV-Related Cervical Carcinoma | Phase 2 | Status: COMPLETED